Pay in 4 interest-free payments of $5.40 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
Sensitivity analyses showed that tirzepatide became less cost-effective than semaglutide at smaller magnitudes of body mass index (BMI) reduction, when using Federal Supply Schedule costs, and when excluding its effects on major adverse cardiovascular events
Food and Drug Administration (FDA) approved semaglutide in December 2017 under the brand name Ozempic for type 2 diabetes treatment
Patients should be informed about the gradual nature of effects, particularly for weight loss
In addition, suspected side effects can be reported directly to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk or through the Yellow Card app
US$ 23.89
US$ 22.44
US$ 25.79
US$ 20.51
